• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Symptomatic abnormal vessel wall reaction after implantation of the first generation sirolimus-eluting stent: a case series.

作者信息

Mostafa Ahmad E, Richardt Gert, Abdel-Wahab Mohamed

机构信息

Heart Center, Segeberger Kliniken GmbH (Academic Teaching Hospital of the University of Kiel), Bad Segeberg, Germany.

出版信息

Cardiovasc Revasc Med. 2012 May-Jun;13(3):196-200. doi: 10.1016/j.carrev.2012.02.008.

DOI:10.1016/j.carrev.2012.02.008
PMID:22652316
Abstract

AIMS

Expansive vessel wall remodeling has been previously reported after implantation of drug-eluting stents. These abnormal vessel wall reactions (AVWR), though uncommon may be associated with serious clinical events. We report on a series of patients in whom symptoms developed despite patent stents.

METHODS AND RESULTS

We report a series of 10 consecutive patients with evidence of AVWR on angiography and/or intravascular ultrasonography after implantation of sirolimus-eluting stents (age 39-90 years, 4 females) during a period of 4 years. All patients were symptomatic despite patent stents in coronary angiographies done because of persistent chest pain. Four patients subsequently developed very late stent thrombosis (VLST). These 4 patients were only on aspirin monotherapy prior to the VLST. Of the remaining 6 patients, 3 patients underwent coronary interventions (with or without stenting) while the remaining 3 patients were managed conservatively. All 6 were advised for life-long dual antiplatelet therapy.

CONCLUSION

Though uncommon, AVWR might precede VLST. In our series, all patients were symptomatic despite patent stents. Additional studies are required to identify patients at risk and to determine the best treatment modality for this challenging new entity. Until further data become available, these patients should stay on dual antiplatelet therapy after an AVWR has been identified.

摘要

相似文献

1
Symptomatic abnormal vessel wall reaction after implantation of the first generation sirolimus-eluting stent: a case series.
Cardiovasc Revasc Med. 2012 May-Jun;13(3):196-200. doi: 10.1016/j.carrev.2012.02.008.
2
First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).首例人体生物可吸收聚合物涂层依维莫司洗脱支架的评估:DESOLVE I 试验(载有依维莫司和生物可吸收聚合物的 DES 治疗原发性冠状动脉病变患者)的影像学和临床结果。
JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013. Epub 2013 Sep 18.
3
Acute myocardial infarction related to very late sirolimus-eluting stent thrombosis 6 months after discontinuation of dual antiplatelet therapy.在停用双联抗血小板治疗6个月后发生的与极晚期西罗莫司洗脱支架血栓形成相关的急性心肌梗死。
J Cardiovasc Med (Hagerstown). 2011 Nov;12(11):839-42. doi: 10.2459/JCM.0b013e328337d7e7.
4
Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.可生物降解聚合物涂层西罗莫司洗脱支架在“真实世界”实践中的安全性和有效性:18个月临床及9个月血管造影结果
JACC Cardiovasc Interv. 2009 Apr;2(4):303-9. doi: 10.1016/j.jcin.2008.12.013.
5
Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.用于治疗单发性初发冠状动脉病变的羟基磷灰石非聚合物西罗莫司洗脱支架的初步结果:第三代药物洗脱支架系统的首次人体分析
JACC Cardiovasc Interv. 2008 Oct;1(5):545-51. doi: 10.1016/j.jcin.2008.07.003.
6
2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.常规临床实践中生物可降解聚合物涂层雷帕霉素洗脱支架与永久性聚合物涂层西罗莫司洗脱支架随机比较的 2 年临床随访。
JACC Cardiovasc Interv. 2011 Aug;4(8):887-95. doi: 10.1016/j.jcin.2011.03.017.
7
Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).晚期临床结果与佐他莫司和西罗莫司洗脱支架。ENDEAVOR III 试验(美敦力 Endeavor 药物 [ABT-578]洗脱冠状动脉支架系统与 Cypher 西罗莫司洗脱冠状动脉支架系统在初发原生冠状动脉病变中的随机对照试验)的 5 年随访结果。
JACC Cardiovasc Interv. 2011 May;4(5):543-50. doi: 10.1016/j.jcin.2010.12.014.
8
Long-term clinical and angiographic outcomes after implantation of sirolimus-eluting stents with a "modified mini-crush" technique in coronary bifurcation lesions.采用“改良迷你挤压”技术植入西罗莫司洗脱支架治疗冠状动脉分叉病变后的长期临床及血管造影结果
Catheter Cardiovasc Interv. 2009 Jul 1;74(1):76-84. doi: 10.1002/ccd.22020.
9
Impact of intravascular ultrasound imaging on early and late clinical outcomes following percutaneous coronary intervention with drug-eluting stents.血管内超声成像对药物洗脱支架经皮冠状动脉介入治疗后早期和晚期临床结局的影响。
JACC Cardiovasc Interv. 2011 Sep;4(9):974-81. doi: 10.1016/j.jcin.2011.07.005.
10
Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.尽管在急性心肌梗死中成功进行了机械干预,但导丝插入后持续无复流是一个早期且易于获得的死亡风险因素:来自 STRATEGY(单次大剂量替罗非班和西罗莫司洗脱支架与阿昔单抗和裸金属支架治疗急性心肌梗死)和 MULTISTRATEGY(多中心评估单次大剂量替罗非班与阿昔单抗与西罗莫司洗脱支架或裸金属支架治疗急性心肌梗死的研究)试验的汇总分析。
JACC Cardiovasc Interv. 2011 Jan;4(1):51-62. doi: 10.1016/j.jcin.2010.09.016.

引用本文的文献

1
Rapamycin impairs endothelial cell function in human internal thoracic arteries.雷帕霉素损害人胸廓内动脉的内皮细胞功能。
Eur J Med Res. 2015 Jun 24;20(1):59. doi: 10.1186/s40001-015-0150-4.